Identifying differences between biochemical failure and cure: Incidence rates and predictors

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Vicini, Frank A ^a   Shah, Chirag ^a   Kestin, Larry ^a   Ghilezan, Mihai ^a   Krauss, Daniel ^a   Ye, Hong ^a   Brabbins, Donald ^a   Martinez, Alvaro A ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Biochemical cure; Biochemical failure; Nadir; Prostate cancer; Radiation therapy

Indexed keywords

AFTER-TREATMENT; BIOCHEMICAL CURE; BIOCHEMICAL FAILURE; BRACHYTHERAPY; HIGH-RISK PATIENTS; INCIDENCE RATE; MULTI VARIATE ANALYSIS; NADIR; PELVIC RADIATION; PROSTATE CANCERS; PROSTATE CARCINOMA; PROSTATE SPECIFIC ANTIGEN;

ANTIGENS; CURING; DISEASES; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT MONITORING;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL CURE; BIOCHEMICAL FAILURE; BRACHYTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TREATMENT FAILURE;

EID: 80255132665     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.05.017     Document Type: Article

References (17)

1. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
2. E.M. Horwitz, H.D. Thames, and D.A. Kuban Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis J Urol 173 2005 797 802 (Pubitemid 40239344)
3. D.L. Fitch, S. McGrath, and A.A. Martinez Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation Int J Radiat Oncol Biol Phys 66 2006 1430 1439
4. A. Thompson, M. Keyes, and T. Pickles Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78 2010 415 421
5. A.J. Stephenson Is the Phoenix definition superior to ASTRO for predicting clinical outcomes in prostate cancer? Nat Clin Pract Urol 5 2008 356 357
6. C.A. Bellera, J.A. Hanley, and L. Joseph A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1357 1363
7. M.C. Abramowitz, T. Li, and M.K. Buyyounouski The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Cancer 112 2008 55 60
8. R.G. Stock, T.J. Klein, and J.A. Cesaretti Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy Int J Radiat Oncol Biol Phys 74 2009 753 758
9. A.A. Martinez, D. Yan, and D. Lockman Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer Int J Radiat Oncol Biol Phys 50 2001 1226 1234 (Pubitemid 32727800)
10. D. Yan, D. Lockman, and D. Brabbins An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer Int J Radiat Oncol Biol Phys 48 2000 289 302 (Pubitemid 30488241)
11. A.A. Martinez, I. Pataki, and G. Edmundson Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report Int J Radiat Oncol Biol Phys 49 2001 61 69 (Pubitemid 32041277)
12. C.E. Vargas, A.A. Martinez, and T.P. Boike High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study Int J Radiat Oncol Biol Phys 66 2006 416 423 (Pubitemid 44332728)
13. M.E. Ray, H.D. Thames, and L.B. Levy PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis Int J Radiat Oncol Biol Phys 64 2006 1140 1150
14. I. Aref, L. Eapen, and O. Agboola The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma Radiother Oncol 48 1998 203 207 (Pubitemid 28423793)
15. J.M. Crook, E. Choan, and G.A. Perry Serum prostate-specific antigen profile following radiotherapy for prostate cancer: Implications for patterns of failure and definition of cure Urology 51 1998 566 572 (Pubitemid 28186208)
16. F.A. Critz, K. Levinson, and W.H. Williams Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer Urology 49 1997 668 672 (Pubitemid 27194579)
17. J.J. Coen, C.S. Chung, and W.U. Shipley Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10 year cohort analysis Int J Radiat Oncol Biol Phys 57 2003 621 628 (Pubitemid 37194287)